Differential role of the basolateral amygdala 5-HT3 and 5-HT4 serotonin receptors upon ACPA-induced anxiolytic-like behaviors and emotional memory deficit in mice

Behavioural Brain Research

Volumn 261, Issue , 2014, Pages 114-126

  Chegini, Hamid Reza ^a   Nasehi, Mohammad ^a,b   Zarrindast, Mohammad Reza ^a,c,d,e  

^a INSTITUTE FOR COGNITIVE SCIENCE STUDIES ICSS   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e INSTITUTE FOR RESEARCH IN FUNDAMENTAL SCIENCES IPM   (Iran)

Author keywords

Anxiety; Elevated plus maze; Emotional memory; Mouse; Serotonergic agent

Indexed keywords

1 (3 CHLOROPHENYL)BIGUANIDE; 1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; 4 AMINO 5 CHLORO 2 METHOXYBENZOIC ACID 3 PIPERIDINOPROPYL ESTER; ARACHIDONYLCYCLOPROPYLAMIDE; AZASETRON; CANNABINOID 1 RECEPTOR AGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BASOLATERAL AMYGDALA; BEHAVIOR CHANGE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ELEVATED PLUS MAZE TEST; EMOTIONAL DISORDER; LOCOMOTION; MALE; MICROINJECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANXIETY; ELEVATED PLUS-MAZE; EMOTIONAL MEMORY; MOUSE; SEROTONERGIC AGENT;

AMYGDALA; ANALYSIS OF VARIANCE; ANIMALS; ANXIETY DISORDERS; ARACHIDONIC ACIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICROINJECTIONS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, SEROTONIN, 5-HT3; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGENTS;

EID: 84891357550     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.12.007     Document Type: Article

References (159)

1. Watson S.J., Benson J.A., Joy J.E. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry 2000, 57:547-552.
2. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
3. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
4. Mackie K.N., Cannabinoid Receptores S., Endocannabinoids Evidence for new players. AAPS 2006, 8:298-306.
5. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152:1092-1101.
6. Chaperon F., Thiebot M.H. Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999, 13:243-281.
7. Nasehi M., Piri M., Jamali-Raeufy N., Zarrindast M.R. Influence of intracerebral administration of NO agents in dorsal hippocampus (CA1) on cannabinoid state-dependent memory in the step-down passive avoidance test. Physiol Behav 2010, 100:297-304.
8. Nasehi M., Sahebgharani M., Haeri-Rohani A., Zarrindast M.R. Effects of cannabinoids infused into the dorsal hippocampus upon memory formation in 3-days apomorphine-treated rats. Neurobiol Learn Memory 2009, 92:391-399.
9. Rodgers R.J., Haller J., Halasz J., Mikics E. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur J Neurosci 2003, 17:1279-1286.
10. Block R.I., Farinpour R., Braverman K. Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques. Pharmacol Biochem Behav 1992, 43:907-917.
11. Chait L.D., Perry J.L. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psychopharmacology (Berl) 1994, 115:340-349.
12. Court J.M. Cannabis and brain function. J Paediatr Child Health 1998, 34:1-5.
13. Cox M.L., Haller V.L., Welch S.P. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. Eur J Pharmacol 2007, 570:50-56.
14. Heishman S.J., Arasteh K., Stitzer M.L. Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav 1997, 58:93-101.
15. Moreira F.A., Cannabinoids Wotjak C.T., anxiety. Curr Top Behav Neurosci 2010, 2:429-450.
16. Scherma M., Medalie J., Fratta W., Vadivel S.K., Makriyannis A., Piomelli D., et al. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 2008, 54:129-140.
17. Sullivan J.M. Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. Learn Mem 2000, 7:132-139.
18. Ruehle S., Rey A.A., Remmers F., Lutz B. The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol 2012, 26:23-39.
19. Viveros M.P., Marco E.M., File S.E. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 2005, 81:331-342.
20. Cheer J.F., Cadogan A.K., Marsden C.A., Fone K.C., Kendall D.A. Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 1999, 38:533-541.
21. Devlin M.G., Christopoulos A. Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J Neurochem 2002, 80:1095-1102.
22. Haring M., Marsicano G., Lutz B., Monory K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 2007, 146:1212-1219.
23. Costall B., Naylor R.J. 5-HT3 receptors. Curr Drug Targets CNS Neurol Disorders 2004, 3:27-37.
24. Bruss M., Eucker T., Gothert M., Bonisch H. Exon-intron organization of the human 5-HT3A receptor gene. Neuropharmacology 2000, 39:308-315.
25. Hope A.G., Downie D.L., Sutherland L., Lambert J.J., Peters J.A., Burchell B. Cloning and functional expression of an apparent splice variant of the murine 5-HT3 receptor A subunit. Eur J Pharmacol 1993, 245:187-192.
26. Miquel M.C., Emerit M.B., Gingrich J.A., Nosjean A., Hamon M. el Mestikawy S. Developmental changes in the differential expression of two serotonin 5-HT3 receptor splice variants in the rat. J Neurochem 1995, 65:475-483.
27. Davies P.A., Pistis M., Hanna M.C., Peters J.A., Lambert J.J., Hales T.G., et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999, 397:359-363.
28. van Hooft J.A., Yakel J.L. 5-HT3 receptors in the CNS: 3B or not 3B. Trends Pharmacol Sci 2003, 24:157-160.
29. Roth BL. The serotonin receptors, from molecular pharmacology to human therapeutics. Totowa, New Lersey: Human Press; 2006.
30. Langlois M., Fischmeister R. 5-HT4 receptor ligands: applications and new prospects. J Med Chem 2003, 46:319-344.
31. Inoue T., Koyama T., Yamashita I. Effect of conditioned fear stress on serotonin metabolism in the rat brain. Pharmacol Biochem Behav 1993, 44:371-374.
32. Inoue T., Tsuchiya K., Koyama T. Regional changes in dopamine and serotonin activation with various intensity of physical and psychological stress in the rat brain. Pharmacol Biochem Behav 1994, 49:911-920.
33. Ji W., Suga N. Serotonergic modulation of plasticity of the auditory cortex elicited by fear conditioning. J Neurosci 2007, 27:4910-4918.
34. Ogren S.O., Eriksson T.M., Elvander-Tottie E., D'Addario C., Ekstrom J.C., Svenningsson P., et al. The role of 5-HT(1A) receptors in learning and memory. Behav Brain Res 2008, 195:54-77.
35. Meneses A. A pharmacological analysis of an associative learning task: 5-HT(1) to 5-HT(7) receptor subtypes function on a pavlovian/instrumental autoshaped memory. Learn Mem 2003, 10:363-372.
36. Barnes J.M., Barnes N.M., Champaneria S., Costall B., Naylor R.J. Characterisation and autoradiographic localisation of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat. Neuropharmacology 1990, 29:1037-1045.
37. Hannon J., Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res 2008, 195:198-213.
38. Kilpatrick G.J., Jones B.J., Tyers M.B. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 1987, 330:746-748.
39. Olivier B., van Wijngaarden I., Soudijn W. 5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol 2000, 10:77-95.
40. Tecott L.H., Maricq A.V., Julius D. Nervous system distribution of the serotonin 5-HT3 receptor mRNA. Proc Natl Acad Sci U S A 1993, 90:1430-1434.
41. Thompson A.J., Lummis S.C. 5-HT3 receptors. Curr Pharm Des 2006, 12:3615-3630.
42. Kennett G.A., Bright F., Trail B., Blackburn T.P., Sanger G.J. Anxiolytic-like actions of the selective 5-HT4 receptor antagonists SB 204070A and SB 207266A in rats. Neuropharmacology 1997, 36:707-712.
43. Fanselow M.S., Poulos A.M. The neuroscience of mammalian associative learning. Annu Rev Psychol 2005, 56:207-234.
44. LeDoux J.E. Emotion circuits in the brain. Annu Rev Neurosci 2000, 23:155-184.
45. Lichtman A.H., Varvel S.A., Martin B.R. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 2002, 66:269-285.
46. Maren S. Neurobiology of Pavlovian fear conditioning. Annu Rev Neurosci 2001, 24:897-931.
47. Marsicano G., Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 1999, 11:4213-4225.
48. Krettek J.E., Price J.L. A description of the amygdaloid complex in the rat and cat with observations on intra-amygdaloid axonal connections. J Comp Neurol 1978, 178:255-280.
49. Rodriguez J.J., Mackie K., Pickel V.M. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 2001, 21:823-833.
50. Tsou K., Mackie K., Sanudo-Pena M.C., Walker J.M. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 1999, 93:969-975.
51. Zarrindast M.R., Nasehi M., Khansari M., Bananej M. Influence of nitric oxide agents in the rat amygdala on anxiogenic-like effect induced by histamine. Neurosci Lett 2011, 489:38-42.
52. Sajdyk T.J., Shekhar A. Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Brain Res 1997, 764:262-264.
53. Sanders S.K., Shekhar A. Regulation of anxiety by GABAA receptors in the rat amygdala. Pharmacol Biochem Behav 1995, 52:701-706.
54. Truitt W.A., Johnson P.L., Dietrich A.D., Fitz S.D., Shekhar A. Anxiety-like behavior is modulated by a discrete subpopulation of interneurons in the basolateral amygdala. Neuroscience 2009, 160:284-294.
55. Adolphs R., Denburg N.L., Tranel D. The amygdala's role in long-term declarative memory for gist and detail. Behav Neurosci 2001, 115:983-992.
56. Adolphs R., Tranel D., Buchanan T.W. Amygdala damage impairs emotional memory for gist but not details of complex stimuli. Nat Neurosci 2005, 8:512-518.
57. Canli T., Zhao Z., Brewer J., Gabrieli J.D., Cahill L. Event-related activation in the human amygdala associates with later memory for individual emotional experience. J Neurosci 2000, 20:RC99.
58. Dolcos F., LaBar K.S., Cabeza R. Interaction between the amygdala and the medial temporal lobe memory system predicts better memory for emotional events. Neuron 2004, 42:855-863.
59. McGaugh J.L. The amygdala modulates the consolidation of memories of emotionally arousing experiences. Annu Rev Neurosci 2004, 27:1-28.
60. Barad M. Fear extinction in rodents: basic insight to clinical promise. Curr Opin Neurobiol 2005, 15:710-715.
61. Quirk G.J., Gehlert D.R. Inhibition of the amygdala: key to pathological states. Ann N Y Acad Sci 2003, 985:263-272.
62. Wall P.M., Messier C. Concurrent modulation of anxiety and memory. Behav Brain Res 2000, 109:229-241.
63. Kalueff A.V. Neurobiology of memory and anxiety: from genes to behavior. Neural Plast 2007, 2007:78171.
64. Asth L., Lobao-Soares B., Andre E., Soares Vde P., Gavioli E.C. The elevated T-maze task as an animal model to simultaneously investigate the effects of drugs on long-term memory and anxiety in mice. Brain Res Bull 2012, 87:526-533.
65. Zarrindast M.R., Naghdi-Sedeh N., Nasehi M., Sahraei H., Bahrami F., Asadi F. The effects of dopaminergic drugs in the ventral hippocampus of rats in the nicotine-induced anxiogenic-like response. Neurosci Lett 2010, 475:156-160.
66. Bertoglio L.J., Carobrez A.P. Previous maze experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety. Behav Brain Res 2000, 108:197-203.
67. Fernandes C., File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav 1996, 54:31-40.
68. Gianlorenco A.C., Canto-de-Souza A., Mattioli R. Microinjection of histamine into the cerebellar vermis impairs emotional memory consolidation in mice. Brain Res Bull 2011, 86:134-138.
69. Lee C., Rodgers R.J. Antinociceptive effects of elevated plus-maze exposure: influence of opiate receptor manipulations. Psychopharmacology (Berl) 1990, 102:507-513.
70. Stern C.A., Do Monte F.H., Gazarini L., Carobrez A.P., Bertoglio L.J. Activity in prelimbic cortex is required for adjusting the anxiety response level during the elevated plus-maze retest. Neuroscience 2010, 170:214-222.
71. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 1993, 44:463-469.
72. Hermann H., Marsicano G., Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002, 109:451-460.
73. Morales M., Wang S.D., Diaz-Ruiz O., Jho D.H. Cannabinoid CB1 receptor and serotonin 3 receptor subunit A (5-HT3A) are co-expressed in GABA neurons in the rat telencephalon. J Comp Neurol 2004, 468:205-216.
74. Lutz B. The endocannabinoid system and extinction learning. Mol Neurobiol 2007, 36:92-101.
75. Witkin J.M., Tzavara E.T., Nomikos G.G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 2005, 16:315-331.
76. Barann M., Molderings G., Bruss M., Bonisch H., Urban B.W., Gothert M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 2002, 137:589-596.
77. Ju Yeon B., Yeon Hee S. Blockade of 5-HT(3) receptor with MDL 72222 and Y 25130 reduces beta-amyloid protein (25--35)-induced neurotoxicity in cultured rat cortical neurons. Eur J Pharmacol 2005, 520:12-21.
78. Meneses A. Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: short- and long-term memory. Behav Brain Res 2007, 184:81-90.
79. Ortega J.E., Mendiguren A., Pineda J., Meana J.J. Regulation of central noradrenergic activity by 5-HT(3) receptors located in the locus coeruleus of the rat. Neuropharmacology 2012, 62:2472-2479.
80. Yousefi B., Farjad M., Nasehi M., Zarrindast M.R. Involvement of the CA1 GABAA receptors in ACPA-induced impairment of spatial and non-spatial novelty detection in mice. Neurobiol Learn Memory 2013, 100:32-40.
81. Paxinos G, Franklin, KBJ. The mouse brain in stereotaxic coordinates. 2nd Ed. Academic Press; 2001.
82. Nasehi M., Piri M., Abdollahian M., Zarrindast M.R. Involvement of nitrergic system of CA1 in harmane induced learning and memory deficits. Physiol Behav 2012.
83. Nasehi M., Sharifi S., Zarrindast M.R. Involvement of the cholinergic system of CA1 on harmane-induced amnesia in the step-down passive avoidance test. J Psychopharmacol 2012, 26:1151-1161.
84. Serafim K.R., Gianlorenco A.C., Daher F.P., Mattioli R. H(1)-histamine receptors in the amygdala are involved in emotional memory but do not mediate anxiety-related behaviors in mice submitted to EPM testing. Brain Res Bull 2012, 89:1-7.
85. Zarrindast M.R., Hoseindoost S., Nasehi M. Possible interaction between opioidergic and cholinergic systems of CA1 in cholestasis-induced amnesia in mice. Behav Brain Res 2012, 228:116-124.
86. Nasehi M., Amin Yavari S., Zarrindast M.R. Synergistic effects between CA1 mu opioid and dopamine D1-like receptors in impaired passive avoidance performance induced by hepatic encephalopathy in mice. Psychopharmacology 2013, 227:553-566.
87. Ahmadi H., Nasehi M., Rostami P., Zarrindast M.R. Involvement of the nucleus accumbens shell dopaminergic system in prelimbic NMDA-induced anxiolytic-like behaviors. Neuropharmacology 2013, 71:112-123.
88. Motevasseli T., Rezayof A., Zarrindast M.R., Nayer-Nouri T. Role of ventral hippocampal NMDA receptors in anxiolytic-like effect of morphine. Physiol Behav 2010, 101:608-613.
89. Nikseresht S., Etebary S., Karimian M., Nabavizadeh F., Zarrindast M.R., Sadeghipour H.R. Acute administration of zn, mg, and thiamine improves postpartum depression conditions in mice. Arch Iran Med 2012, 15:306-311.
90. Bertoglio L.J., Joca S.R., Guimaraes F.S. Further evidence that anxiety and memory are regionally dissociated within the hippocampus. Behav Brain Res 2006, 175:183-188.
91. File S.E. The interplay of learning and anxiety in the elevated plus-maze. Behav Brain Res 1993, 58:199-202.
92. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
93. Da Cunha I.C., Jose R.F., Orlandi Pereira L., Pimenta J.A., Oliveira de Souza I.A., Reiser R., et al. The role of nitric oxide in the emotional learning of rats in the plus-maze. Physiol Behav 2005, 84:351-358.
94. Bertoglio L.J., Carobrez A.P. Scopolamine given pre-Trial 1 prevents the one-trial tolerance phenomenon in the elevated plus-maze Trial 2. Behav Pharmacol 2004, 15:45-54.
95. Holmes A., Rodgers R.J. Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for a qualitative shift in emotional state. Pharmacol Biochem Behav 1998, 60:473-488.
96. Carobrez A.P., Ethological Bertoglio L.J. temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 2005, 29:1193-1205.
97. Lamprea M.R., Cardenas F.P., Silveira R., Morato S., Walsh T.J. Dissociation of memory and anxiety in a repeated elevated plus maze paradigm: forebrain cholinergic mechanisms. Behav Brain Res 2000, 117:97-105.
98. Yildiz Akar F., Ulak G., Tanyeri P., Erden F., Utkan T., Gacar N. 7-Nitroindazole, a neuronal nitric oxide synthase inhibitor, impairs passive-avoidance and elevated plus-maze memory performance in rats. Pharmacol Biochem Behav 2007, 87:434-443.
99. Cole J.C., Rodgers R.J. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology 1994, 114:288-296.
100. Bertoglio L.J., Carobrez A.P. Behavioral profile of rats submitted to session 1-session 2 in the elevated plus-maze during diurnal/nocturnal phases and under different illumination conditions. Behav Brain Res 2002, 132:135-143.
101. Onaivi E.S., Green M.R., Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990, 253:1002-1009.
102. Marco E.M., Perez-Alvarez L., Borcel E., Rubio M., Guaza C., Ambrosio E., et al. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol 2004, 15:21-27.
103. Berrendero F., Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology 2002, 163:111-117.
104. Haller J., Bakos N., Szirmay M., Ledent C., Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002, 16:1395-1398.
105. Uriguen L., Perez-Rial S., Ledent C., Palomo T., Manzanares J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 2004, 46:966-973.
106. Haller J., Matyas F., Soproni K., Varga B., Barsy B., Nemeth B., et al. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 2007, 25:2445-2456.
107. Jentsch J.D., Andrusiak E., Tran A., Bowers M.B., Roth R.H. Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 1997, 16:426-432.
108. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
109. Costanzi M., Battaglia M., Rossi-Arnaud C., Cestari V., Castellano C. Effects of anandamide and morphine combinations on memory consolidation in cd1 mice: involvement of dopaminergic mechanisms. Neurobiol Learn Memory 2004, 81:144-149.
110. Mishima K., Egashira N., Hirosawa N., Fujii M., Matsumoto Y., Iwasaki K., et al. Characteristics of learning and memory impairment induced by delta9-tetrahydrocannabinol in rats. Jap J Pharmacol 2001, 87:297-308.
111. Laviolette S.R., Grace A.A. Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdala inputs. J Neurosci 2006, 26:6458-6468.
112. Laviolette S.R., Grace A.A. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 2006, 63:1597-1613.
113. McDonald A.J., Mascagni F. Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons. Neuroscience 2001, 107:641-652.
114. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
115. Molina-Holgado F., Amaro A., Gonzalez M.I., Alvarez F.J., Leret M.L. Effect of maternal delta 9-tetrahydrocannabinol on developing serotonergic system. Eur J Pharmacol 1996, 316:39-42.
116. Garcia-Gil L., de Miguel R., Romero J., Perez A., Ramos J.A., Fernandez-Ruiz J.J. Perinatal delta9-tetrahydrocannabinol exposure augmented the magnitude of motor inhibition caused by GABA(B), but not GABA(A), receptor agonists in adult rats. Neurotoxicol Teratol 1999, 21:277-283.
117. Vela G., Fuentes J.A., Bonnin A., Fernandez-Ruiz J., Ruiz-Gayo M. Perinatal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) leads to changes in opioid-related behavioral patterns in rats. Brain Res 1995, 680:142-147.
118. Vela G., Martin S., Garcia-Gil L., Crespo J.A., Ruiz-Gayo M., Javier Fernandez-Ruiz J., et al. Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats. Brain Res 1998, 807:101-109.
119. Schlicker E., Timm J., Gothert M. Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn-Schmiedeberg's Arch Pharmacol 1996, 354:791-795.
120. Fernandez-Ruiz J., Berrendero F., Hernandez M.L., Ramos J.A. The endogenous cannabinoid system and brain development. Trends Neurosci 2000, 23:14-20.
121. Fernandez-Ruiz J.J., Berrendero F., Hernandez M.L., Romero J., Ramos J.A. Role of endocannabinoids in brain development. Life Sci 1999, 65:725-736.
122. Ehrlich I., Humeau Y., Grenier F., Ciocchi S., Herry C., Luthi A. Amygdala inhibitory circuits and the control of fear memory. Neuron 2009, 62:757-771.
123. Pitkanen A., Savander V., LeDoux J.E. Organization of intra-amygdaloid circuitries in the rat: an emerging framework for understanding functions of the amygdala. Trends Neurosci 1997, 20:517-523.
124. Roozendaal B., McEwen B.S., Chattarji S. Stress, memory and the amygdala. Nat Rev Neurosci 2009, 10:423-433.
125. Wang D.V., Wang F., Liu J., Zhang L., Wang Z., Lin L. Neurons in the amygdala with response-selectivity for anxiety in two ethologically based tests. PloS One 2011, 6:e18739.
126. Smith H.R., Porrino L.J. The comparative distributions of the monoamine transporters in the rodent, monkey, and human amygdala. Brain Struct Funct 2008, 213:73-91.
127. Abrams J.K., Johnson P.L., Hay-Schmidt A., Mikkelsen J.D., Shekhar A., Lowry C.A. Serotonergic systems associated with arousal and vigilance behaviors following administration of anxiogenic drugs. Neuroscience 2005, 133:983-997.
128. Bonn M., Schmitt A., Lesch K.P., Van Bockstaele E.J., Asan E. Serotonergic innervation and serotonin receptor expression of NPY-producing neurons in the rat lateral and basolateral amygdaloid nuclei. Brain Struct Funct 2012.
129. Holmes A. Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev 2008, 32:1293-1314.
130. Kriegebaum C., Gutknecht L., Schmitt A., Lesch K.P., Reif A. Serotonin now: Part 1. Neurobiology and developmental genetics. Fortschritte Neurol-Psych 2010, 78:319-331.
131. Morales M., Wang S.D. Differential composition of 5-hydroxytryptamine3 receptors synthesized in the rat CNS and peripheral nervous system. J. Neurosci. 2002, 22:6732-6741.
132. Carli M., Luschi R., Samanin R. Dose-related impairment of spatial learning by intrahippocampal scopolamine: antagonism by ondansetron, a 5-HT3 receptor antagonist. Behav Brain Res. 1997, 82:185-194.
133. Fontana D.J., Daniels S.E., Henderson C., Eglen R.M., Wong E.H. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology (Berl) 1995, 120:409-417.
134. Meneses A. 5-HT system and cognition. Neurosci biobehav Rev 1999, 23:1111-1125.
135. Bratt A.M., Kelly M.E., Domeney A.M., Naylor R.J., Costall B. Ondansetron fails to attenuate a scopolamine-induced deficit in a Stone maze task. Neuroreport 1994, 5:1921-1924.
136. Arnsten A.F., Lin C.H., Van Dyck C.H., Stanhope K.J. The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiol Aging 1997, 18:21-28.
137. Pitsikas N., Brambilla A. Borsini F. DAU 6215, a novel 5-HT3 receptor antagonist, improves performance in the aged rat in the Morris water maze task. Neurobiol Aging 1993, 14:561-564.
138. Ye J.H., Ponnudurai R., Schaefer R. Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 2001, 7:199-213.
139. Bockaert J., Claeysen S., Compan V., Dumuis A. 5-HT4 receptors. Curr Drug Targets CNS Neurol Disorders 2004, 3:39-51.
140. Maillet M., Robert S.J., Lezoualc'h F. New insights into serotonin 5-HT4 receptors: a novel therapeutic target for Alzheimer's disease. Curr Alzheimer Res 2004, 1:79-85.
141. Galeotti N., Ghelardini C., Bartolini A. Role of 5-HT4 receptors in the mouse passive avoidance test. J Pharmacol Exp Ther 1998, 286:1115-1121.
142. Letty S., Child R., Dumuis A., Pantaloni A., Bockaert J., Rondouin G. 5-HT4 receptors improve social olfactory memory in the rat. Neuropharmacology 1997, 36:681-687.
143. Marchetti-Gauthier E., Roman F.S., Dumuis A., Bockaert J., Soumireu-Mourat B. BIMU1 increases associative memory in rats by activating 5-HT4 receptors. Neuropharmacology 1997, 36:697-706.
144. Meneses A., Hong E. Effects of 5-HT4 receptor agonists and antagonists in learning. Pharmacol Biochem Behav 1997, 56:347-351.
145. Fontana D.J., Daniels S.E., Wong E.H., Clark R.D., Eglen R.M. The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation. Neuropharmacology 1997, 36:689-696.
146. Lamirault L., Simon H. Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors. Neuropharmacology 2001, 41:844-853.
147. Terry A.V., Buccafusco J.J., Jackson W.J., Prendergast M.A., Fontana D.J., Wong E.H., et al. Enhanced delayed matching performance in younger and older macaques administered the 5-HT4 receptor agonist, RS 17017. Psychopharmacology (Berl) 1998, 135:407-415.
148. Azad S.C., Monory K., Marsicano G., Cravatt B.F., Lutz B., Zieglgansberger W., et al. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 2004, 24:9953-9961.
149. Freund T.F., Hajos N. Excitement reduces inhibition via endocannabinoids. Neuron 2003, 38:362-365.
150. Hofelmann D., di Benedetto B., Azad S.C., Micale V., Wotjak C.T., Rammes G. Lack of interaction of endocannabinoids and 5-HT(3) neurotransmission in associative fear circuits of the amygdala: evidence from electrophysiological and behavioural experiments. Brain Res 2013, 1527:47-56.
151. Haj-Dahmane S., Shen R.Y. The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling. J Neurosci 2005, 25:896-905.
152. Steffens M., Feuerstein T.J. Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex--involvement of Na(+)/K(+)-ATPase. Neurochem Int 2004, 44:529-538.
153. Köfalvi A. Cannabinoids and the brain. New York, NY 10013, USA: Springer Science+Business Media, LLC, 233 Spring Street; 2007.
154. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995, 73:907-910.
155. Darmani N.A., Johnson J.C. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 2004, 488:201-212.
156. Barad M., Gean P.W., Lutz B. The role of the amygdala in the extinction of conditioned fear. Biol Psychiatry 2006, 60:322-328.
157. Chhatwal J.P., Davis M., Maguschak K.A., Ressler K.J. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005, 30:516-524.
158. Chung L., Moore S.D. Cholecystokinin enhances GABAergic inhibitory transmission in basolateral amygdala. Neuropeptides 2007, 41:453-463.
159. Mikics E., Vas J., Aliczki M., Halasz J., Haller J. Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission. Behav Pharmacol 2009, 20:265-272.